Cancerous disease modifying antibodies
View Patent ↗The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
1. The isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as Accession Number PTA-5690.
2. A humanized antibody produced from the isolated monoclonal antibody of claim 1 .
3. Antigen binding fragments of the isolated monoclonal antibody of claim 1 .
4. Antigen binding fragments of the humanized antibody of claim 2 .
5. The isolated monoclonal antibody or antigen binding fragments of any one of claims 1 , 2 , 3 , or 4 conjugated with a member selected from the group consisting of toxins, enzymes, radioactive compounds, and hematogenous cells.
6. The isolated hybridoma deposited with the ATCC as Accession Number PTA-5690.
7. A binding assay to determine presence of cancerous cells in a tissue sample selected from a human colon tumor comprising:
providing a tissue sample from said human colon tumor;
providing an isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as Accession Number PTA-5690 or antigen binding fragment thereof; or an antibody conjugate thereof;
contacting said isolated monoclonal antibody or antigen binding fragment thereof or antibody conjugate thereof with said tissue sample; and
determining binding of said isolated monoclonal antibody or antigen binding fragment thereof or antibody conjugate thereof with said tissue sample;
whereby the presence of said cancerous cells in said tissue sample is indicated.
8. A process of isolating or screening for cancerous cells in a tissue sample selected from a human colon tumor comprising:
providing a tissue sample from said human colon tumor;
providing an isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as Accession Number PTA-5690 or antigen binding fragment thereof; or an antibody conjugate thereof;
contacting said isolated monoclonal antibody or antigen binding fragment thereof or antibody conjugate thereof with said tissue sample; and
determining binding of said isolated monoclonal antibody or antigen binding fragment thereof or antibody conjugate thereof with said tissue sample;
whereby said cancerous cells are isolated by said binding and their presence in said tissue sample is confirmed.